Notch3 and its CADASIL mutants differentially regulate cellular phenotypes

CHUNJING LIN¹, ZIYANG HUANG², RIYONG ZHOU³, YING ZHOU⁴, YANGPING SHENTU⁵, KANG YU² and YU ZHANG²

Departments of ¹Gastroenterology, ²Hematology, ³Anesthesiology, ⁴Nephrology and ⁵Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China

Received February 13, 2020; Accepted July 21, 2020

DOI: 10.3892/etm.2020.9549

Abstract. Notch3 is a member of the Notch family and its mutations are known to cause a hereditary human disorder called cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). However, the specific function and signaling cascade initiated by CADASIL mutants remain unknown. To gain further insight into mechanism of action of CADASIL mutants, the present study conducted several experiments on the effects of Notch3 mutants in multiple cell lines. The protein levels of Notch3, fibronectin, collagen, inducible nitric oxide synthase and DNA (cytosine-5)-methyltransferase 1 (DNMT1) were determined by western blotting. The mRNA levels of IL-1β and TNF-α were measured by reverse transcription semi-quantitative PCR and DNMT1 mRNA levels were determined by quantitative PCR. Trypan blue staining was used for proliferation analysis and wound healing assays were performed to determine cell migration capability. The present study reported that R90C and R169C Notch3 mutants, and wild-type Notch3 had different effects on several cell lines. In T/GHA-VSMC cells, following the transfection of the two mutants, collagen and fibronectin expression increased, whereas expression decreased in IMR-90 cells. In BV2 cells, the two mutants resulted in decreased nitric oxide and iNOS production. In HeLa cells, proliferation and migration increased significantly following the transfection of the two mutants, whereas in the MCF-7 and HCC1937 cell lines, cell proliferation and migration decreased. In addition, the two mutants suppressed the expression of DNMT1 in HeLa and IMR-90 cells. Overall, the present study provided novel insights that further explored the underlying mechanisms of CADASIL.

Introduction

Notch signaling has been demonstrated to participate in cell fate determination and in progenitor cell maintenance during development (1). In mammals, there are four Notch receptors (Notch1-4), which have distinct tissue expression patterns and are considered to function in specific cellular contexts (1). Notch3, a highly conserved type I transmembrane protein, is predominantly expressed in vascular smooth muscle cells (VSMCs) and intracellular domain (ICD), which serves an important role in VSMC maturation and differentiation (2). After binding of a ligand (6-like protein 1 or protein jagged-1b) to the ECD, the protein undergoes three proteolytic cleavage steps, leading to the translocation of the ICD to the nucleus, where it functions as a nuclear transcription factor (3).

Highly stereotyped mutations of ECD have been associated with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), an inherited small vessel disease that causes stroke and dementia (4). The typical characteristic of CADASIL is progressive degeneration of VSMCs in blood vessel walls, accompanied by the accumulation of Notch3 extracellular region and the appearance of granular osmiophilic material deposits (5). In CADASIL, >170 different mutations have been detected (5). Most of these are missense point mutations complemented by a few small deletions that lead to gain or loss of a cysteine residue within an epidermal growth factor-like domain, thus altering the number of cysteine residues within a given domain from 6 to either 5 or 7 (6). This results in an unpaired cysteine that is predicted to disrupt normal disulfide bridge formation, causing misfolding of growth factor-like repeats and increased Notch3 monomerization (7,8). However, the exact underlying mechanism of pathogenesis in CADASIL is yet to be elucidated. The role of CADASIL mutants in the pathogenic mechanism is controversial and several authors have reported that altered Notch3 function is not the primary determinant of the disease (9-11).

Based on the uncertain functions of the CADASIL-Notch3 mutants and the unknown mechanism of CADASIL, the present study aimed to explore the roles of mutants and wild-type (WT) Notch3 in the differential regulation of various cellular phenotypes in several cell lines. The present
findings could serve as a molecular foundation for future studies investigating the underlying mechanism of Notch3 signaling in CADASIL and may provide an important insight for the investigation of novel CADASIL treatments.

Materials and methods

Cells. TiGHA-human aortic VSMCs (CRL-1999), human fetal lung fibroblasts (IMR-90; CCL-186), human cervical cancer cell (HeLa; CCL-2), human breast cancer (MCF-7; CRL-3435) and mouse microglia (BV2 cells;CRL-2468) were obtained from the American Type Culture Collection. Human breast cancer cells (HCC1937 cells; TCHu148) were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. HeLa and MCF-7 cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) whereas the other cell lines were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Beijing Solarbio Science & Technology Co., Ltd.). Cells were maintained in a humidified incubator at 37°C with 5% CO₂. HA-VSMCs and IMR-90 cells were selected to clarify the effect of Notch3 mutants on tunica media and adventitia, respectively. HeLa, MCF-7 and HCC1937 cells were selected to assess the role of Notch3 mutants in different types of cancer, while BV2 cells were used to evaluate the impact of Notch3 mutants on neuroinflammation.

Western blot analysis. Cells were lysed in a sample buffer containing 2% SDS, 60 mM Tris–HCl (pH 6.8) and 5% glycerol. Cell lysates were then boiled for 5 min. Total protein concentration was determined using a BCA kit (Beyotime Institute of Biotechnology), according to the manufacturer's protocol, and equal quantities of proteins were loaded for western blot analysis. In brief, 20 µg proteins were resolved by 10% SDS-PAGE, transferred to a PVDF membrane (Pall Life Sciences) and then blocked with 5% milk in TBS with 0.1% Tween-20 for 1 h at room temperature. The membrane was then incubated with antibodies (1:1,000) against Notch3 (cat. no. SC-5593; Santa Cruz Biotechnology, Inc.), fibronectin (cat. no. 26836; Cell Signaling Technology Co., Ltd.), collagen type I (cat. no. SC-59772; Santa Cruz Biotechnology, Inc.), inducible nitric oxide synthase (iNOS; cat. no. 31120; Cell Signaling Technology, Inc.), DNA (cytosine-5)-methyltransferase 1 (DNMT1; cat. no. 5032; Cell Signaling Technology, Inc.) or β-actin (cat. no. 3700; Cell Signaling Technology, Inc.) overnight at 4°C, followed by incubation with secondary horseradish peroxidase-conjugated anti-rabbit (1:5,000; cat. no. 7074; Cell Signaling Technology, Inc.) or anti-mouse (1:5,000; cat. no. 7076; Cell Signaling Technology, Inc.) antibodies for 1 h at room temperature. Blots were developed using enhanced chemiluminescence reagents (LumiGLO® Reagent and Peroxide; Cell Signaling Technology, Inc.), according to the manufacturer's protocol. Densitometry was performed using ImageJ software (version 1.8.0; National Institutes of Health).

Nitric oxide (NO) release assay. Nitrite level in the cell culture medium was measured as an indicator of NO production. In brief, BV2 cells were treated with LPS (1 µg/ml Sigma-Aldrich; Merck KGaA) for 24 h. Following this, 50 µl supernatant was mixed with an equal volume of Griess reagent I (Beyotime Institute of Biotechnology), followed by addition of 50 µl Griess reagent II (Beyotime Institute of Biotechnology) at room temperature. The absorbance was immediately measured at 540 nm. The samples were assayed in triplicate and the concentration of each sample was calculated from a standard curve generated using sodium nitrite.

Reverse transcription semi-quantitative PCR analysis. Total RNA was extracted from BV2 cells using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed using the PrimeScript™ RT Master Mix (Takara Biotechnology Co., Ltd.), according to the manufacturer's protocol. Conditions for reverse transcription were 15 min at 37°C and 5 sec at 85°C. PCR analyses of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and β-actin mRNA levels were performed using 2X Taq Master Mix (Vazyme Biotech Co., Ltd.). The forward and reverse primer pairs used were as follows: TNF-α forward, 5'-ATCCGGAGCTGGAACGT-3' and reverse, 5'-ACCGCC TGGAAGTTTCGGA-3'; IL-1β forward, 5'-CTTACATCTTT-3' and reverse, 5'-TCACACACACAGGTTTATCTAC-3'; and β-actin forward, 5'-TGGGACCAGACACATGAA-3' and reverse, 5'-CTAAGTCATAATGCTCGGTATAG-3'. The PCR thermocycling conditions were as follows: 95°C for 5 min, followed by 30 cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for 1 min and 72°C for 10 min. The products were separated on a 1.2% agarose gel containing ethidium bromide and were visualized under a gel imaging system.

Quantitative PCR (qPCR) analysis. Total RNA extraction and reverse transcription were carried out as described for semi-quantitative PCR analysis. qPCR analyses of mRNA expression levels were performed with TB Green Premix Ex Taq (Takara Biotechnology Co., Ltd.). The forward and reverse primer pairs were as follows: DNMT1 forward, 5'-GTGGGG GACGTGTTCTCTGTG-3' and reverse, 5'-TGAAGCTGCTGCA TGTCCTCACC-3'; and β-actin forward, 5'-ATCGTGCGTGA CATTAGGAG-3' and reverse, 5'-GAAGGAAGCTGGAGA GGTG-3'. The qPCR thermocycling conditions were as follows: 95°C for 30 sec, followed by 40 cycles of 95°C for 3 sec, 60°C for 30 sec, β-actin was used as the reference gene to normalize the mRNA expression of DNMT1.

Vector construction and transfection. pCMV-Sport6 Notch3 (Genbank ID: NM_000435.3) was provided by Dr Michael Wang (University of Michigan, USA). The R90C and R169C Notch3 CADASIL mutants were generated by PCR mutagenesis of the pCMV-Sport6 Notch3 vector using the following primers: R90C forward, 5'-CCCC TGTGCTGCTGTTGTTGTTGCT-3' and reverse, 5'-GGGCGACACCCACACCAACCAAGCCAGGGG-3'; and R169C forward, 5'-GGGACGCCCTTGTGGTACGATGA GCA-3' and reverse, 5'-TGCCACCATGCGACAGGCTC ACC-3'. The PCR reaction was performed using Takara PrimeSTAR Max DNA Polymerase (Takara Biotechnology Co., Ltd.), according to the manufacturer's protocol. The PCR thermocycling conditions were as follows: 98°C for 3 min, followed by 30 cycles of 98°C for 30 sec, 60°C for 30 sec, 72°C for 5 min and 72°C for 10 min. The authenticity of the cloned fragments was confirmed by sequencing. A total of 2 µg vectors were transfected into 5x10⁵ cells using...
Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. After 48 h of transfection, cells were collected for further experiments.

**Proliferation assay.** A total of 3x10⁵ cells were seeded in 12-well plates and allowed to grow for 24 h prior to plasmid transfection. At 24 h post-transfection, the cells were trypsinized at 0, 12, 24 and 48 h. Following this, 10 µl aliquots of cells were incubated with 10 µl 0.4% trypan blue solution for 5 min at room temperature. Cells that exhibited trypan blue (viable cells) were counted using a light microscope (magnification, x100; ECLIPSE Ti; Nikon Corporation) with a hemocytometer (12).

**Wound healing assay.** Wound healing assays were performed as described by Song et al (13). Briefly, 3x10⁵ cells were seeded in 12-well plates overnight and transfected with the vectors. Cells were grown to confluence for 36 h after transfection and wounded by scratching the monolayer with a 200-µl pipette tip. Following this, the cells were washed using pre-warmed PBS to remove cellular debris and allowed to migrate for 24 h in medium containing 1% FBS. Images of cell migration were captured at 0 and 24 h after wounding using a light microscope (magnification, x200; ECLIPSE Ti; Nikon Corporation). The relative distance between the leading edges was determined using NIS-Elements Documentation software (version no. 4.10; Nikon Corporation) and expressed as a migration index (the distance migrated in 24 h relative to the initial gap).

**Statistical analysis.** Data were analyzed using one-way ANOVA with Tukey's post hoc test using the statistical package of SPSS software (version 18; SPSS, Inc.) for Windows. Data are expressed as the mean ± standard error of the mean from ≥3 independent experiments. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**CADASIL mutants differentially regulate the expression of extracellular matrix proteins in VSMCs and fibroblasts.** A pathological study demonstrated that marked fibrotic thickening of arteriolar walls occurs in patients with CADASIL (14). Based on these data, CADASIL mutants R90C and R169C were transfected into HA-VSMCs and IMR-90 cells to elucidate the molecular mechanism of fibrosis. The results from the western blot analysis revealed that the expression level of extracellular matrix collagen and fibronectin were significantly increased after the transfection of mutants (however, this did not occur in WT) in HA-VSMCs (Fig. 1A), which is consistent with
CADASIL pathology (15). By contrast, the results showed a different trend in IMR-90 cells, where collagen and fibronectin were significantly decreased after transfection of mutants; however, this did not occur in WT (Fig. 1B). These results indicated that there was differential regulation of the extracellular matrix between CADASIL mutants and Notch3 WT in VSMCs and fibroblasts.

**CADASIL mutants downregulate the levels of NO and iNOS in microglia.** It has been reported that the activated Notch signaling pathway regulate the proliferation and differentiation of neural precursor cells, mediate the release of inflammatory mediators and promote angiogenesis (16). Additionally, it serves an important role in nerve damage repair, inflammatory response and angiogenesis in ischemic areas (17). Abnormal regulation of glial cells was observed in patients with CADASIL (18). Thus, it was hypothesized that inflammation may be involved in the pathogenesis of CADASIL. According to the aforementioned findings, R90C and R169C Notch3 mutants, as well as Notch3 WT, were transfected into BV2 cells to study their roles in the regulation of the inflammatory response following LPS administration. The transfection efficiency of R90C, R169C and WT Notch3 vectors was confirmed by western blotting (Fig. 2A). mRNA analysis showed that the expression levels of TNF-α and IL-1β were not altered by transfection with the mutants compared with those transfected with WT Notch3 with or without LPS treatment (Fig. 2B). Next, the level of NO in the culture medium was detected. The results showed that the NO level of the cells transfected with mutants was significantly lower compared with the cells transfected with WT with or without LPS treatment (Fig. 2C). Furthermore, the protein level of iNOS was in accordance with the change in NO (Fig. 2D). This indicated that downregulation of NO, which is a vasodilator factor, may be involved in the pathogenesis of CADASIL.

**CADASIL mutants promote the proliferation and migration of HeLa cells; however, they inhibit those of breast cancer cells.** It has been reported that Notch3 protein, which is present in numerous types of tumors, serves an important role in promoting tumor progression (19). In the present study, HeLa cells were used to assess the effects of the mutants on cell proliferation and migration, in which no apparent difference was observed among Notch3-transfected and EV-transfected cells. All Notch3 vectors effectively enhanced Notch3 expression in HeLa cells (Fig. 3A). Exogenous expression of WT Notch3 led to a significant increase in cell proliferation (Fig. 3B) and migration (Fig. 3C); however, R90C and R169C exhibited a stronger promoter effect on HeLa cells compared with WT. The aforementioned results showed that both WT and CADASIL mutants were involved in the regulation of the phenotype in HeLa cells; however, the regulatory effects of CADASIL mutants were more apparent compared with WT. Additional cancer cells were employed to explore whether the malignancy-promoting effect of Notch3 is cell-specific or general. Notch3 proteins were remarkably increased in MCF-7 cells by Notch3 mutants and WT vectors transfection (Fig. 4A). Notably, opposite outcomes to those observed in HeLa cells were observed in MCF-7 cells transfected with mutants, since the expression of exogenous Notch3 mutants significantly inhibited the proliferation of MCF-7 cells at 48 h compared with the results upon transfection with EV at 12, 24 and 48 h, and those transfected with WT (Fig. 4B). The results of the wound healing assay showed that overexpression of Notch3 mutants significantly inhibited the migration of MCF-7 cells compared with cells transfected with WT (Fig. 4C). There was no significant difference between transfected mutants and EV on the migration of MCF-7 cells. In view of the aforementioned results, it was concluded that this differential regulation may be associated with the type of cancer cells. To further verify this conclusion, HCC1937 cells, which are also breast cancer
cells, were selected for further investigation. HCC1937 cells and MCF-7 cells exhibited similar changes in proliferation and migration following transfection of CADASIL mutants (Fig. 5A-C). These results suggested that the differential regulation of phenotype between CADASIL mutants R90C and R169C and WT was associated with cell type.

**CADASIL mutants downregulate DNMT1 in HeLa and IMR-90 cells.** DNMT1 serves a critical role in the maintenance of the genetic stability of methylation sites during replication (20). Abnormal expression of DNMT1 can lead to unusual DNA methylation and further affect gene expression and disease progression (20). The present study assessed the regulation of CADASIL mutants and Notch3 WT on DNMT1 as a preliminary exploration of the underlying mechanism. The results showed that CADASIL mutants significantly downregulated the protein expression of DNMT1 in HeLa (Fig. 6A) and IMR-90 (Fig. 6B) cells, whereas WT had no effect. To further explore the mechanism underlying CADASIL mutants-mediated reduction of DNMT1, mRNA expression of DNMT1 was analyzed. The data implied that CADASIL mutants reduced the mRNA expression of DNMT1 in HeLa (Fig. 6C) and IMR-90 (Fig. 6D) cells, indicating that the regulatory events may occur at the transcriptional level. This suggested that there may be deregulation of DNA methylation in CADASIL, which may provide a novel insight for the exploration of subsequent pathogenesis.

**Discussion**

Mutations in genes encoding Notch proteins lead to a range of dysfunctions and diseases (21). Notch1 mutations have been reported in a wide variety of human diseases, including Adams-Oliver syndrome (22), left-sided congenital heart disease (23) and bicuspid aortic valve disease (24). Notch2 mutations are involved in the development of Alagille syndrome (25), while mutations in Notch3 can cause CADASIL. Diseases associated with Notch4 mutations have not been thoroughly studied (21). The most common mutations of Notch3 in CADASIL are R133C, R141C, R182C, R153C, R169C and R90C (26). In the present study, R90C and R169C CADASIL-Notch3 mutants and Notch3 WT had different
impacts on several cell lines, suggesting that Notch3 mutants may have more biological functions beyond current knowledge.

Stenosis of cerebral white matter arterioles with fibrosis and thickening of their walls have been attributed to accumulation of various extracellular matrix components, which can lead to decreased cerebral blood flow to such a severity that lacunar infarcts occur in CADASIL (18). It had been reported that, in diseased arteries, types I, III and VI collagen spread from an external location (adventitia) into the vascular media, while type IV collagen accumulated in an internal pattern (intima and media) (27), which is consistent with the present results. No major leakage of plasma fibrinogen or fibronectin was observed in a previous study (15). In the present study, fibronectin was observed to increase in HA-VSMCs following transfection with mutants, whereas in IMR-90 cells, collagen and fibronectin were decreased following transfection. Oide et al (28) reported that extensive arterial medial smooth muscle cells and arterial adventitia extracellular matrix were lost in CADASIL, which led to diffuse leukoencephalopathy. It is commonly known that the adventitia is primarily composed of fibroblasts. According to the aforementioned results, it was suggested that Notch3 mutants affected the physiological characteristics of arteries by two mechanisms: i) Upregulation of extracellular matrix in VSMCs, which may induce fibrotic thickening of arteriolar; and ii) downregulation of extracellular matrix in fibroblasts, which may deprive the structural and functional ability of the cerebrovascular system to regulate the cerebral blood flow, most likely due to the loss of arterial medial smooth muscle cells and mural extracellular matrix.

Neuroinflammation mediated by microglia serves an important role in damage of the central nervous system and prognosis of the disease (18). In a previous study, activation of the Notch signaling pathway caused nerve damage, which contributed to the infiltration of inflammatory cells via microglia activation (17). Abnormal regulation of glial cells was observed in patients with CADASIL (29). Thus, a microglial cell model of CADASIL was established to study the regulation of CADASIL mutants on the inflammatory response. Both NO and iNOS levels observed in two mutants groups were much lower compared with the WT group with or without LPS treatment. Considering that NO is a factor that contributes to vasodilatation and patients with CADASIL often

---

Figure 4. Inhibitory effect of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy mutants on MCF-7 cell malignancy. (A) EV, WT, R90C and R169C were transfected into MCF-7 cells and Notch3 protein expression was detected by western blotting. (B) The numbers of EV-, WT-, R90C- and R169C-transfected cells were counted at 0-48 h post-transfection. (C) The results of the wound healing assay are expressed as the migration index (the distance migrated relative to the initial scraped gap) and that of EV-transfected cells was set as 100%. Data are presented as mean ± standard error of the mean (n=3). *P<0.05 vs. EV-transfected cells; †P<0.05 vs. WT-transfected cells. EV, empty vector; WT, wild-type.
suffer ischemic stroke or subcutaneous infarction, limited NO availability may contribute to an increase in the resting vasomotor tone and, therefore, may serve an important role in cerebral ischemia (30). It has been reported that cerebral vasoreactivity enhanced by L-arginine, which is the substrate for NOS, may have therapeutic implications for CADASIL (31). In terms of a pathogenic role of impaired cerebral hemodynamics and endothelial dysfunction in CADASIL, it was hypothesized that Notch3 mutants may also affect the synthesis of NO in endothelial cells. However, further studies are required to explore this.

Notch3 primarily serves a role in promoting cancer development and it has been detected in multiple types of tumor, including ovarian, cervical, breast and colon cancer (19). Compared with the effects of Notch3 WT, CADASIL mutants promoted the proliferation and migration of HeLa cells and inhibit these of breast cancer cells. A previous study observed hyperplasia in organs, including the liver, kidney and prostate in patients with CADASIL (32). The autopsy examination of a Japanese case revealed that, besides the vascular and neurological lesions characteristic of CADASIL, multiple neoplastic lesions were also observed, including carcinoid tumorlets and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia in the lungs, renal cell carcinoma, prostatic adenocarcinoma and adenomatoid tumor of the epididymis (33). Combined with the present data, this suggested that Notch3 mutants may contribute to the increased or decreased risks of different cancer types in CADASIL.

Cerebral small vessel disease (CSVD) is one of the most common nervous system disease worldwide (1920-2017) and is considered an important pathological process of subcortical structures such as lacunar infarcts, white matter lesions and microbleeds (34). CSVD is an important cerebral microvascular pathogenesis, since it is the cause of 20% of strokes worldwide (1920-2017) and the most common cause of cognitive impairment and dementia, including vascular dementia (34). It has been reported that CSVD contributes to the occurrence of Alzheimer's disease (AD) and CADASIL (35). The association between epigenetics and CSVD has not yet been established; however, research on cerebrovascular
diseases and DNA methylation are gradually increasing, particularly on DNA methylation abnormalities in stroke (36). A previous study that discovered the mechanism of cerebral small vessel injury aided the present study (36). Furthermore, another previous study reported that DNA methylation served an important role in gene transcription, gene imprinting and embryo development (20). DNMT1 primarily maintained the genetic stability of the methylation site during the replication process and its abnormal expression lead to dysregulation of DNA methylation, therefore affecting gene expression and disease progression (20). To the best of our knowledge, the present study is the first to report that CADASIL mutants significantly inhibited DNMT1 mRNA and protein expression in both HeLa and IMR-90 cells, whereas WT Notch3 had no effect.

Multiple studies have revealed that abnormal DNA methylation was associated with AD (37,38). Both the mRNA and protein levels of DNMT1 and DNMT3α, as well as those of methyl CpG binding protein 2, have been demonstrated to be downregulated in AD (39). However, the exact underlying mechanism remains to be discovered. It was reported that a pathogenic presenilin mutation in AD caused a specific increase in p53 protein (40), which was found to block the transcription of the DNMT1 gene by binding to its promoter region in hepatocellular carcinoma, ovarian cancer and pancreatic ductal adenocarcinoma (41). Whether the downregulation of DNMT1 in CADASIL and AD was also regulated by p53-mediated transcriptional inhibition needs to be further explored. The present data suggested that there may be an abnormal regulation of DNA methylation in CADASIL, which provides a novel approach for the exploration of subsequent pathogenesis.

In summary, the present study revealed that Notch3 mutants had differential effects depending on cell type, suggesting that Notch3 mutants may have more biological functions beyond our current knowledge. These results provided novel avenues for further research on the pathogenesis of CADASIL and future studies need to be carried out to elucidate the specific pathways or underlying mechanisms of this differential regulation.
Haploinsufficiency of the NOTCH1 Receptor as a loss-of-function mechanism. Stroke 45: 842‑849, 2014.

Competing interests
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Bray SJ: Notch signalling in context. Nat Rev Mol Cell Biol 17: 722‑735, 2016.
2. Domenga V, Fardoux P, Lacombe P, Monet M, Maciak J, Krebs LT, Klönjkowski B, Berrou E, Merciscky M, Li Z, et al: Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 18: 2730‑2735, 2004.
3. Wang T, Baron M and Trump D: An overview of Notch3 function in vascular smooth muscle cells. Prog Biophys Mol Biol 96: 499‑509, 2008.
4. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cécillion M, Marechal E, et al: Notch3 mutations in CADASIL, a hereditary adult‑onset condition causing stroke and dementia. Nature 383: 707‑710, 1996.
5. Hervé D and Chabriat H: CADASIL. J Geriatr Psychiatry Neurol 23: 269‑276, 2010.
6. Joutel A, Vahedi K, Corpechot C, Trosch A, Chabriat H, Vayssière C, Crucq A, Maciak J, Weissenbach J, Bousser MG, et al: Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350: 1511‑1515, 1997.
7. Dichgans M, Ludwig H, Müller‑Höcker J, Messerschmidt A and Gasser T: Small in‑frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF‑like repeat domains. Eur J Hum Genet 8: 280‑285, 2000.
8. Duering M, Karpinska A, Rosner S, Hofner F, Zecheimster M, Peters N, Kremmer E, Haffner C, Giese A, Dichgans M, et al: Co‑aggregate formation of CADASIL‑mutant NOTCH3: A single‑particle analysis. Hum Mol Genet 20: 3256‑3265, 2011.
9. Cognat E, Baron‑Menguy C, Domenga‑Denier V, Cleophas S, Fouillade C, Monet‑Leprétrie M, Dewerchin M and Joutel A: Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss‑of‑function mechanism. Stroke 45: 842‑849, 2014.
10. Joutel A: Pathogenesis of CADASIL: Transgenic and knock‑out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature. BioEssays 33: 73‑80, 2011.
11. Ruttoun JW, Haan J, Terrinod GM, van Duinen SG, Böckers TM, Kolvin Lernik OB: Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. Expert Rev Mol Diagn 14: 593‑603, 2014.
12. Yamaguchi N, Oyama T, Ito E, Sato H, Asuma S, Hayashi M, Shiraçu K, Honma R, Yanagisawa Y, Nishikawa A, et al: NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2‑negative human breast cancer cells. Cancer Res 68: 1881‑1888, 2008.
13. Song G, Zhang Y and Wang L: MicroRNA‑206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 284: 31921‑31927, 2009.
14. Miao Q, Paloneva T, Tuisku S, Roine S, Poyhonen M, Vitiainen M and Kalimo H: Arterioles of the lenticular nucleus in CADASIL. Stroke 37: 2242‑2247, 2006.
15. Dong H, Blairas M and Wang MM: Bidirectional encroachment of collagen into the tunica media in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Brain Res 1456: 64‑71, 2012.
16. Grandarpa L, Michelucci A, Heurtas T, Hemmer K, Monge E and Heuschling P: Notch signaling modulates the activation of peripheral cells. Glia 55: 1510‑1530, 2007.
17. Yao L, Cao Q, Wu C, Kaur C, Hao A and Ling EA: Notch signaling in the central nervous system with special reference to its expression in microglia. CNS Neurol Disord Drug Targets 12: 807‑814, 2013.
18. Dichgans M: Cognition in CADASIL. Stroke 40 (Suppl): S45‑S47, 2009.
19. Aburjania Z, Jang S, Whitt J, Jaskula‑Stzul R, Chen H and Rose JB: The Role of Notch3 in Cancer. Oncologist 23: 900‑911, 2018.
20. Edwards JR, Yaruchikviva O, Boulaud M and Bestor TH: DNA methylation and DNA methyltransferases. Epigenetics Chromatin 10: 23, 2017.
21. Meester JAN, Verstraeten A, Alaerts M, Schepers D, Van Laer L, Kerstjens‑Frederikse WS, van de Laar IM, Vos YJ, Verhagen JM, Anomalies. Circ Cardiovasc Genet 8: 572‑581, 2015.
22. Joss S, et al: Strong clustering and stereotyped nature of Notch3 mutations in CADASIL, a hereditary adult‑onset condition causing stroke and dementia. Nature 383: 707‑710, 1996.
23. Kurstjens‑Frederikse WS, van de Laar IM, Vos YJ, Verhagen JM, Anomalies. Circ Cardiovasc Genet 8: 572‑581, 2015.
24. Haritunians T, Chow T, De Lange RP, Nichols JT, Ghavimi D, McDaniell R, Warthen DM, Sanchez‑Lara PA, Pai A, Krantz ID, Piccoli DA and Spinner NB: NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 79: 169‑173, 2006.
25. Rutten JW, Haan J, Terrinod GM, van Duinen SG, Böckers TM, Kolvin Lernik OB: Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. Expert Rev Mol Diagn 14: 593‑603, 2014.
30. DeMartino AW, Kim-Shapiro DB, Patel RP and Gladwin MT: Nitrite and nitrate chemical biology and signalling. Br J Pharmacol 176: 228-245, 2019.
31. Peters N, Freilinger T, Opferk C, Pfefferkorn T and Dichgans M: Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. J Neurol 255: 1203-1208, 2008.
32. Ling Y, De Guio F, Jouvent E, Duering M, Hervé D, Guichard JP, Godin O, Dichgans M and Chabrier H: Clinical correlates of longitudinal MRI changes in CADASIL. J Cereb Blood Flow Metab 39: 1299-1305, 2019.
33. Hassan WA, Udaka N, Ueda A, Ando Y and Ito T: Neoplastic lesions in CADASIL syndrome: Report of an autopsied Japanese case. Int J Clin Exp Pathol 8: 7533-7539, 2015.
34. Søndergaard CB, Nielsen JE, Hansen CK and Christensen H: Hereditary cerebral small vessel disease and stroke. Clin Neurol Neurosurg 155: 45-57, 2017.
35. Müller K, Courtois G, Ursini MV and Schwaninger M: New Insight Into the Pathogenesis of Cerebral Small-Vessel Diseases. Stroke 48: 520-527, 2017.
36. Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, Sparrow D, Vokonas P and Schwartz J: Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 21: 819-828, 2010.
37. Altuna M, Urdánoz-Casado A, Sánchez-Ruiz de Gordo J, Zelaya MV, Labarga A, Lepesant JMJ, Roldán M, Blanco-Luquin I, Penedones A, Larumbe R, et al: DNA methylation signature of human hippocampus in Alzheimer's disease is linked to neurogenesis. Clin Epigenetics 11: 91, 2019.
38. Yokoyama AS, Rutledge JC and Medici V: DNA methylation alterations in Alzheimer's disease. Environ Epigenet 3: dvx008, 2017.
39. Bihadi SW and Zawia NH: Alzheimer's disease biomarkers and epigenetic intermediates following exposure to Pb in vitro. Curr Alzheimer Res 9: 555-562, 2012.
40. Bialopiotrowicz E, Szybinska A, Kuzniewska B, Buizza L, Uberti D, Kuznicki J and Wojda U: Highly pathogenic Alzheimer's disease presenilin 1 P117R mutation causes a specific increase in p53 and p21 protein levels and cell cycle dysregulation in human lymphocytes. J Alzheimers Dis 32: 397-415, 2012.
41. Enane FO, Saunthararajah Y and Korc M: Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9: 912-926, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.